NCT06596473 2026-03-05
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
59 trialsNCT07387068 2026-03-04
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07446816 2026-03-03
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05620017 2026-02-09
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Phase 1 Recruiting
NCT06480552 2026-02-05
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT07215637 2026-02-02
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1 Recruiting
NCT07377591 2026-01-30
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06792552 2026-01-29
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Phase 1 Recruiting
NCT07042100 2026-01-22
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT06770569 2026-01-21
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Recruiting
NCT07356453 2026-01-21
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
Phase 1 Recruiting
NCT06927570 2026-01-16
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07186452 2026-01-16
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07231458 2026-01-16
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
Phase 1 Recruiting
NCT06990464 2026-01-08
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT07252414 2026-01-05
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06384352 2026-01-02
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT07310134 2026-01-02
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1 Recruiting
NCT06882135 2025-12-29
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Recruiting
NCT07230977 2025-12-24
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07251166 2025-12-24
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07266285 2025-12-17
BTM-3566 in Advanced Solid Tumors
Bantam Pharmaceuticals
Phase 1 Recruiting
NCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT06736327 2025-12-08
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06428331 2025-12-05
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06826040 2025-12-05
SKB445 for Injection in Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT07208136 2025-12-01
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Jemincare
Phase 1 Recruiting
NCT06238401 2025-11-24
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1 Recruiting
NCT05367635 2025-11-17
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06618651 2025-11-17
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT07229898 2025-11-17
A Phase â… Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
Henan Genuine Biotech Co., Ltd.
Phase 1 Recruiting
NCT06840886 2025-09-04
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT06694480 2025-09-03
Study of FID-022 in Participants With Advanced Solid Tumors
Fulgent Pharma LLC.
Phase 1 Recruiting
NCT07100249 2025-08-08
A Study of HDM2012 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05701709 2025-07-22
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05881525 2025-07-16
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase 1 Recruiting
NCT06719362 2025-07-10
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
Phase 1 Recruiting
NCT07004296 2025-06-08
A Study of HDM2005 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06532565 2025-05-16
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT06968572 2025-05-13
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
Haisco Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT06954558 2025-05-01
GUARDIAN
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Recruiting
NCT06907628 2025-04-25
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06094556 2025-04-13
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06096974 2025-04-09
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1 Recruiting
NCT06167317 2025-03-12
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT06443489 2025-03-05
A Trial of SHR-4849 in Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06394414 2025-02-24
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT06773091 2025-02-11
NKSOLID
Shanghai NK Cell Technology Co., LTD
Phase 1 Recruiting
NCT06801470 2025-02-07
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
Phase 1 Recruiting